These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Arrhythmic risk in essential hypertension: late potentials]. Palmiero P; Maiello M Minerva Cardioangiol; 2004 Feb; 52(1):1-8. PubMed ID: 14765032 [TBL] [Abstract][Full Text] [Related]
45. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies. Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328 [TBL] [Abstract][Full Text] [Related]
46. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy. Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210 [TBL] [Abstract][Full Text] [Related]
47. Clinical methods for the detection and management of left ventricular hypertrophy. Swamy RS; Lang RM Indian Heart J; 2010; 62(5):384-7. PubMed ID: 23189877 [TBL] [Abstract][Full Text] [Related]
48. Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide. Lokhandwala Y; Damle A Curr Med Res Opin; 2004 May; 20(5):639-44. PubMed ID: 15140328 [TBL] [Abstract][Full Text] [Related]
49. Hypertension and the heart. Lip GY; Gammage MD; Beevers DG Br Med Bull; 1994 Apr; 50(2):299-321. PubMed ID: 8205460 [TBL] [Abstract][Full Text] [Related]
50. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Gottdiener JS Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345 [No Abstract] [Full Text] [Related]
51. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor. Messerli FH; Ketelhut R J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540 [TBL] [Abstract][Full Text] [Related]
52. Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study. Magometschnigg D; Brandt D; Hofmann R; Sihorsch K; Stoschitzky K; Zangeneh M; Zenker G Int J Clin Pharmacol Ther; 1997 Sep; 35(9):389-96. PubMed ID: 9314093 [TBL] [Abstract][Full Text] [Related]
53. Ambulatory blood pressure monitoring--comparison with office blood pressure in patients on antihypertensive therapy in private practice. Ker JA; van Wyk CJ; Rheeder P S Afr Med J; 1998 Feb; 88(2):133-5. PubMed ID: 9717494 [TBL] [Abstract][Full Text] [Related]
54. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy. Rosei EA J Hypertens; 2001 Dec; 19(12):2288-90. PubMed ID: 11725178 [No Abstract] [Full Text] [Related]
55. LVH and hypertension: is treating the pressure not enough? Mandell BF Cleve Clin J Med; 2010 Jun; 77(6):344. PubMed ID: 20516242 [No Abstract] [Full Text] [Related]
56. Regression of left ventricular hypertrophy: lodestar to stroke prevention in the treatment of hypertension? Kizer JR; Devereux RB Am J Hypertens; 2006 May; 19(5):439-42. PubMed ID: 16647610 [No Abstract] [Full Text] [Related]
57. [Hypertension and heart disease]. Gerdts E; Omvik P; Mo R; Kjeldsen SE Tidsskr Nor Laegeforen; 2004 Mar; 124(6):802-5. PubMed ID: 15039815 [TBL] [Abstract][Full Text] [Related]
59. Signal averaged ECG in different patterns of left ventricular hypertrophy and geometry in hypertension. Wojszwiłło A; Łoboz-Grudzień K; Jaroch J Kardiol Pol; 2003 May; 58(5):335-43. PubMed ID: 14523481 [TBL] [Abstract][Full Text] [Related]